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Summary
Polyethylene glycol (PEG) conjugated asparaginase (PEGasparaginase) is
essential for treatment of paediatric acute lymphoblastic leukaemia. We
developed an assay identifying antibodies against the PEG-moiety, the lin-
ker and the drug itself in patients experiencing hypersensitivity reactions to
PEGasparaginase. Eighteen patients treated according to the DCOG ALL-11
protocol, with a neutralizing hypersensitivity reaction to PEGasparaginase
to the first PEGasparaginase doses in induction (12 patients) or during
intensification after interruption of several months (6 patients) were
included. ELISA was used to measure antibodies, coating with the succin-
imidyl succinate linker conjugated to BSA, PEGfilgrastim and Escherichia
coli asparaginase, and using hydrolysed PEGasparaginase and mPEG5,000 for
competition. Anti-PEG antibodies were detected in all patients (IgG 100%;
IgM 67%) of whom 39% had anti-PEG antibodies exclusively. Pre-existing
anti-PEG antibodies were also detected in patients who not previously
received a PEGylated therapeutic (58% IgG; 21% IgM). Antibodies against
the SS-linker were predominantly detected during induction (50% IgG;
42% IgM). Anti-asparaginase antibodies were detected in only 11% during
induction but 94% during intensification. In conclusion, anti-PEG and
anti-SS-linker antibodies predominantly play a role in the immunogenic
response to PEGasparaginase during induction. Thus, switching to native
E. coli asparaginase would be an option for adequate asparaginase treat-
ment.
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Asparaginase treatment is essential for childhood acute lym-
phoblastic leukaemia (ALL) treatment. The drug depletes
extracellular asparagine, an essential amino acid for leukemic
cells, selectively killing these cells (Muller & Boos, 1998).
Because asparaginase is derived from bacteria, patients can
develop antibodies to the non-human epitopes, neutralizing
the drug completely. Neutralizing reactions can present with
or without symptoms of an allergy, the latter being called
silent inactivation (Oettgen et al, 1970; Peterson et al, 1971;
Killander et al, 1976; Tong et al, 2014). These reactions
mainly occur after an interruption of asparaginase treatment,
during which anti-asparaginase antibody levels increase
(Tong, et al, 2014). Three forms of asparaginase are clinically
available which are derived from either Escherichia coli or
Erwinia chrysanthemi. By conjugating native E. coli
asparaginase with polyethylene glycol (PEG), the drug is less
immunogenic (Abuchowski et al, 1977a; Abuchowski et al,
1977b; Knop et al, 2010). Therefore, PEGylated E.coli
asparaginase (PEGasparaginase) is used for the treatment of
paediatric ALL (Amylon et al, 1999; Rizzari et al, 2001; Sil-
verman et al, 2001; Duval et al, 2002; Pession et al, 2005;
Moghrabi et al, 2007). In case of a hypersensitivity reaction,
patients have to switch from PEGasparaginase to asparagi-
nase derived from Erwinia chrysanthemi bacteria for adequate
treatment (Pieters et al, 2011).
PEGasparaginase consists of E. coli derived asparaginase, a
345 kDa tetramer to which 69–82 molecules of mPEG
chains are conjugated using a succinimidyl succinate linker
(SS-linker) on the e-amino groups of lysine residues of the
protein. Although PEGylation reduces the immunogenicity of
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asparaginase, neutralizing hypersensitivity reactions still occur
(Tong et al, 2014). Surprisingly, these reactions seem to shift
to the first PEGasparaginase doses in induction and not nec-
essarily during the intensification course after an interruption
of treatment, as seen in our patient cohort. This leads to the
question whether antibodies to the PEG moiety or even the
SS-linker may cause these reactions.
Although PEGylation decreases the immunogenicity of bio-
therapeutics, it has been reported that repeated administration
of PEGylated therapeutics can induce anti-PEG antibodies
associated with hypersensitivity reactions and rapid clearance
Armstrong et al, 2007; Verhoef et al, 2014). Anti-PEG antibod-
ies have been reported in patients treated with PEG conjugated
uricase and PEGinesatide, erythropoietin that is covalently
attached to PEG and withdrawn from the market after severe
hypersensitivity reactions (Hershfield et al, 2014). Also in ALL-
patients treated with PEGasparaginase, the formation of anti-
PEG antibodies has been associated with rapid clearance of the
drug (Armstrong et al, 2007).
We hypothesize that reactions to PEGasparaginase may be
partly triggered by anti-PEG antibodies. Secondly, we
hypothesize that the SS-linker can expose a neo-antigen to
which antibodies can be formed. The linker contains an ester
group which has limited stability at neutral pH in vitro and
is subject to hydrolysis by endogenous esterases in vivo (Car-
ter & Meyerhoff, 1985) The exposed succinate group may
function as an hapten, enhancing immunogenicity (Carter &
Meyerhoff, 1985; Turecek et al, 2016).
Because of the lack of proper developed anti-PEG anti-
body assays, especially lacking proper controls, the aim of
this study was to develop a sensitive and specific assay to
detect possible antibodies to both PEG and the SS-linker. For
this we identified patients who had a neutralizing allergy to
or silent inactivation of PEGasparaginase during the first
administrations (induction phase) or after an interruption of
PEGasparaginase treatment (intensification phase).
Methods
Patients and treatment protocol
Eighteen children with ALL treated according to the Dutch
Childhood Oncology Group (DCOG) ALL-11 protocol
between April 2012 and December 2016, who had developed
a neutralizing hypersensitivity reaction (silent inactivation or
allergy) to PEGasparaginase, were selected for the develop-
ment of the assay. The DCOG ALL-11 protocol (Dutch Trial
Register: NTR3379), including use of patient material, was
approved by the Institutional Review Board and informed
consent was obtained from patients >12 years old, parents or
guardians in accordance with the declaration of Helsinki.
According to the DCOG ALL-11 protocol, all patients
started with the induction phase containing prednisolone, vin-
cristine daunorubicin, and PEGasparaginase (1500 IU/m2 i.v.
administered at day 12, 26 and 40). After induction, patients
were stratified in a standard, medium or high risk group. In
this study, all patients with a hypersensitivity reaction after
induction were treated according to the medium risk group.
After induction, two consolidation courses were given leading
to an asparaginase-free interval of approximately 12 weeks.
Thereafter, medium risk patients were treated with 14 PEGas-
paraginase doses, individualized based on asparaginase activity
levels, in the intensification phase. If a hypersensitivity reaction
occurred, patients were switched to Erwinia asparaginase.
To study the reactions specifically observed during the first
PEGasparaginase doses, 12 patients with a neutralizing hyper-
sensitivity reaction during the induction phase and 6 patients
with a reaction during the intensification phase were selected
(Table I). The antibodies were quantified in serum obtained
within 2 weeks after the reaction. Allergies were graded
according to the Common Terminology Criteria for Adverse
Events (CTCAE) version 4.03.
Asparaginase activity
Whole blood was taken prior to each PEGasparaginase
administration and centrifuged at 800 g for 10 min at room
temperature (RT). Samples were stored at 20°C. PEGas-
paraginase activity levels were measured after thawing using
the L-aspartic b-hydroxamate (AHA) assay as described ear-
lier (Lanvers et al, 2002). Inactivation of PEGasparaginase is
defined as PEGasparaginase activity level <100 IU/l at day
7  1 after administration and/or a trough PEGasparaginase
activity level (14  1 days after a dose) below the limit of
detection (<10 IU/l).
Size-exclusion chromatography of PEGasparaginase
The hydrolysis of mPEG5,000 from PEGasparaginase (Oncas-
par, Shire, Amsterdam, the Netherlands) was investigated by
size-exclusion chromatography. PEGasparaginase and native
E. coli asparaginase (Paronal, Medac, Wedel, Germany) were
diluted to 100 IU/ml in 0.1 mol/l sodium bicarbonate buffer
pH95 (Sigma Aldrich Zwijndrecht, the Netherlands) or PBS
pH 74 (Fisher BioReagents, Landsmeer, the Netherlands) at
RT for 30 h to investigate the dissociation at different pH.
Size-exclusion chromatography was performed on a Waters
2695-Separations Module connected to a Waters 2414-Refrac-
tive Index Detector and a Waters 2487 Dual k-Absorbance
Detector (Waters Corporation, Milford, MA, USA) to which a
PL-Aquagel-OH mixed 8 µm column (Agilent Technologies,
Santa Clara, USA) was attached. Protein concentration was
determined by UV-absorbance at 280 and 210 nm, the latter
to correct for background. PEG polymer concentration was
determined by the refractive index detector. Samples were
incubated in one of the above buffers, and, over a 30 h time
period at RT, injected at 1 ml/min flowrate. The use of size-ex-
clusion chromatography allowed to separate the PEG from
asparaginase and determine the concentration of both compo-
nents over time as a results of hydrolysis.
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Synthesis of the PEG BSA conjugate
BSA (Sigma Aldrich, Zwijndrecht, the Netherlands) was con-
jugated to succinic anhydride (BSA-SS) (Sigma-Aldrich, Zwi-
jndrecht, the Netherlands) or n-ethyl maleimide (BSA-MAL)
(Sigma-Aldrich, Zwijndrecht, the Netherlands) at a molar
ratio of 1:10 in 0.1 mol/l sodium carbonate pH85, to model
the exposed linker upon PEG hydrolysis. The pH was kept
constant by adding 0.1 mol/l sodium hydroxide to the reac-
tion. Upon conjugation, both solutions were dialyzed against
0.1 mol/l sodium carbonate pH85 and subsequently against
PBS at 4°C. Protein concentration was determined by the
PierceTM BCA Protein Assay (Thermo Fisher Scientific, Breda,
the Netherlands). Samples were stored at 20°C.
Anti-drug antibody determination
To investigate the specificity of antibodies against asparagi-
nase, PEG and the SS-linker, an enzyme-linked immunosor-
bent assay (ELISA) was developed coating medium binding
Costar 96-well ELISA plates (Corning, Amsterdam, the
Netherlands) with 04 IU/l PEGasparaginase, 14 IU/l native
E. coli asparaginase, or 1 µg/ml of PEGfilgrastim (Neulasta,
Amgen), filgrastim (Neupogen, Amgen), BSA or BSA-SS in
PBS overnight. PEGfilgrastim, a 19 kDa protein to which a
20 kDa PEG is coupled by aldehyde chemistry using selective
N-terminal amine conjugation, was used to investigate anti-
PEG antibodies. Patient sera were screened for anti-filgrastim
and anti-BSA antibodies to rule out false positive results.
Plates were blocked with 2–5% BSA dissolved in PBS for a
minimum of 2 h at room temperature. Patient sera were
incubated for 2 h in block buffer. Plates were washed 5 times
with 005% 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate CHAPS (Merck Chemicals, Amsterdam, the
Netherlands) in PBS. IgG and IgM were detected by rabbit
polyclonal anti-IgG or anti-IgM (Abcam, Cambridge, UK).
Patients were positive for antibodies if binding exceeded
the cut-off point calculated by absorbance value of sera
obtained from patients before their first PEGasparaginase
administration who did not experience a hypersensitivity
reaction (n = 26) as well as sera obtained from healthy
donors (n = 11) (Mini Donor Dienst, UMCU, the Nether-
lands). The cut-off point for PEGfilgrastim and PEGasparagi-
nase was determined in the presence of 01% mPEG5,000 to
exclude binding of possible pre-existing anti-PEG antibodies,
which have been reported by others (Garay et al, 2012).
Specificity of antibodies was determined by competition
with different concentrations of E. coli asparaginase,
mPEG5,000, or hydrolysed PEGasparaginase. For this, PEGas-
paraginase was diluted to 375 IU/ml in a 0.1 mol/l sodium
carbonate buffer pH 98 and stored for 20 h at 37°C. Sam-
ples were concentrated by centrifugation in Vivaspin20
tubes (GE-Healthcare, the Netherlands) and diluted in PBS.
The pH was adjusted to pH74 by dropwise addition of
1 mol/l HCl.
To exclude any nonspecific competition of mPEG5,000, its
competitive properties were investigated in a varicella zoster
virus (VZV) ELISA, as all patients are expected to be positive
for VZV-antibodies. A polyclonal TransChromo bovine anti-
PEG IgG antibody (Bristol-Myer Squibb, USA) was provided
by Bristol-Myers Squibb to serve as a positive control.
Statistics
SPSS Statistics (IBM Corp, Armonk, New York, USA) ver-
sion 21.0 and GraphPad Prism (GraphPad Software, Inc, La
Jolla, USA) version 5.01 for Windows were used for statisti-
cal analyses. Cut-offs are defined as the mean plus one stan-
dard deviation. To compare the titers of different antibodies,
relative titers were calculated by dividing the patient titer by
the corresponding minimal required dilution. Relative titers
were plotted with boxplots, with the 25, 50 and 75th per-
centiles in the boxes and the ranges indicated by whiskers.
Dose response curves for the competition analyses were fitted
using nonlinear regression.
RESULTS
Table I shows the 18 patients included as described in the
Methods section. Of those, nine patients had silent inactivation
of PEGasparaginase (6 patients during induction, 3 during
intensification); the other patients had an allergy. Asparaginase
activity levels measured after this allergic reaction were below
the limit of quantification in all patients. Two patients had an
allergic reaction against the first dose. Thus, only a small
amount of PEGasparaginase was administered.
Antibodies against asparaginase and PEG
Presence of anti-PEGasparaginase antibodies, which could be
directed to any epitope in the molecule, was investigated (Fig
1, Table I). Anti-PEGasparaginase IgG was detected in 92%
(11/12) and 100% of the patients in respectively the induc-
tion and intensification phase; anti-PEGasparaginase IgM in
67% (8/12) and 83% (5/6). Antibody titers were higher for
IgG than for IgM.
Specificity against asparaginase or PEG was investigated by
coating plates with native E. coli asparaginase or PEGfilgras-
tim (Table II). In patients with a hypersensitivity reaction
during induction, anti-asparaginase IgG was detected in 17%
(2/12) and IgM in none of the patients. In contrast, these
antibodies were detected in 83% (5/6) and 33% (2/6) of the
patients with a reaction during intensification (Fig 1B, Tables
I and II). All patients were positive for anti-PEG IgG anti-
bodies, whereas 75% (9/12) and 50% (3/6) of patients were
positive for anti-PEG IgM in the induction and intensifica-
tion phase, respectively (Fig 1C, Tables I and II).
All patients were negative for anti-filgrastim IgG and IgM.
Anti-PEG titers were around 1009 higher for anti-PEG IgG
than for anti-PEG IgM. Patients with undetectable
R. Kloos et al
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PEGasparaginase levels in combination with an allergic reac-
tion had higher anti-PEG IgG titers than patients with silent
inactivation. Although the anti-PEG titers were lower in the
nine patients with silent inactivation, 6 out of these 9 patients
were exclusively positive for anti-PEG antibodies (Table I).
Specificity towards PEG was confirmed by mPEG5,000 competi-
tion and validated by a polyclonal anti-PEG IgG antibody (Fig
2A) (Dong et al, 2015). Specificity of mPEG5,000 to compete
solely with anti-PEG antibodies was confirmed by its non-
competitive properties to anti-VZV antibodies (Fig 2D).
Pre-existing anti-PEG IgG antibodies were detected in
58% (14/24) and anti-PEG IgM in 21% (5/24) patients (Fig
2C). These patients did not experience any hypersensitivity
reaction to or neutralization of PEGasparaginase during
asparaginase treatment.
Antibodies against the SS-linker
We found that PEG is rapidly hydrolysed from PEGasparagi-
nase when incubated in sodium bicarbonate pH95 (Fig 3A).
Fig 1. Shows the titers relative to the minimal required dilution per epitope for IgG and IgM in patients with a hypersensitivity reaction during
the induction and intensification. Each graph also show the percentage of patients positive for the antibodies during induction (n = 12) and
intensification (n = 6). The relative titers were obtained by dividing the titers measured by the corresponding minimal required dilutions. (A)
Shows the relative titers of anti-PEGasparaginase antibodies. (B) Shows the relative titers of anti-native Escherichia coli asparaginase antibodies.
(C) Shows the relative titers of anti-PEG antibodies. Minimal required dilutions (MRD): Anti-PEGasparaginase IgG 10009; IgM 20009; native
E. coli asparaginase IgG 10009; IgM 20009; PEG-filgrastim IgG 759, IgM 759.
Table II. Antibodies against asparaginase, PEG
and the SS-linker in patients with a reaction to
PEGasparaginase during induction or intensifi-
cation.
Type of antibodies
Induction n = 12 Intensification n = 6
IgG (%) IgM (%) IgG (%) IgM (%)
Anti-PEGasparaginase antibodies 92 67 100 83
Anti-Asparaginase antibodies 17 0 83 33
Anti-PEG antibodies 100 75 100 50
Anti-SS-linker antibodies 50 42 17 17
PEGasparaginase: anti-PEG and -linker antibodies
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Specificity of anti-PEGasparaginase antibodies towards the
SS-linker was determined by coating plates with BSA-SS.
Anti-BSA-SS IgG was detected in 50% (6/12) and 17% (1/6)
during the induction and intensification phase; anti-linker
IgM in 42% (5/12) and 17% (1/6) (Fig 3B, Tables I and II).
No antibodies were found against unmodified BSA or the
unrelated BSA-MAL linker (Fig 3C). Competition by hydrol-
ysed PEGasparaginase inhibited IgG and IgM binding
towards BSA-SS in a dose-dependent manner (Fig 3D).
DISCUSSION
In this study we assessed the specificity of anti-drug antibodies
in paediatric ALL patients treated with PEGasparaginase who
had a neutralizing hypersensitivity reaction (silent inactivation
or allergy) to the drug during the induction or intensification
phase (Tong et al, 2014; van der Sluis et al, 2018). The patients
were selected, though randomly, and the conclusions stated
below should be confirmed by larger patient samples.
Patients with a hypersensitivity reaction to PEGasparagi-
nase developed IgG and IgM antibodies towards
asparaginase, the PEG chain and the linker. The incidence of
anti-E. coli asparaginase antibodies in our sample was lower
during induction (IgG 17% (2/12); IgM 0%) than intensifica-
tion (IgG: 83% (5/6); IgM: 33% (2/6)), indicating that
asparaginase antibodies are mainly developed in an PEGas-
paraginase-free period and are primarily IgG. Patients with a
reaction during induction mainly had anti-PEG (100% IgG
Fig 2. Shows the specificity of the anti-PEG antibodies in normalized dose-response curves. Gradually added mPEG5,000 concentrations competed
with the PEGfilgrastim, decreasing the extinction relative to the extinction without competition (%). (A) Shows the normalized dose-response
curve for anti-PEG IgG with PEG-competition (n = 5) and the polyclonal anti-PEG IgG (pAb) as a positive control. (B) Shows the percentage of
signal remaining after PEG competition for IgM (n = 6), which has an approximately 1009 lower affinity for mPEG5k than IgG. (C) Shows nor-
malized anti-PEG binding of patient samples obtained prior to the first PEGasparaginase dose, who did not have any symptoms of hypersensitiv-
ity or increased clearance of PEGasparaginase during treatment, in (+) or without () the presence of 01% mPEG5,000. (D) Shows binding of
healthy donor serum to varicella zoster virus antigen in the presence of different mPEG5,000 concentrations. Also dilutions of sera are shown to
indicate the doses-response relation in this assay.
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and 75% IgM of 12 patients) and anti-succinate linker anti-
bodies (50% IgG and 42% IgM of 12 patients). Thus, after a
hypersensitivity reaction during the first PEGasparaginase
administrations, patients might benefit from a switch to
native E. coli asparaginase instead of Erwinia asparaginase for
adequate treatment.
In contrast to E. coli asparaginase antibodies, the patients
from our cohort were positive for anti-PEG IgG and IgM anti-
bodies during hypersensitivity reactions both treatment phases.
Mainly patients with an allergy had high anti-PEG antibody
titers, suggesting that these antibodies may induce clinical
symptoms of an allergy. Also, 39% (7/18) with a hypersensitiv-
ity reaction had exclusively anti-PEG antibodies, confirming
the neutralizing capacity of these antibodies. Overall, IgM
titers were low compared to anti-PEG IgG suggesting isotype
class switching. Previous articles suggest that anti-PEG anti-
bodies are predominantly induced through a T-cell indepen-
dent manner (Ishida et al, 2007). Production of anti-drug
antibodies that bypass T-cells are typically IgM or low-affinity
IgG (Baker et al, 2010). Binding of these antibodies can form
immune complexes that are recognized by Fc- or complement-
receptors promoting uptake by antigen processing cells such as
splenic marginal B-cells (Krishna & Nadler, 2016). The pres-
ence of pre-existing anti-PEG antibodies suggest a mechanism
of memory B-cells. Although effective B-cell memory requires
involvement of Th-cells, there is growing evidence that T-cell
independent type II antigens can form B-cell memory (Good-
Jacobson & Tarlinton, 2012). T-cell independent type II anti-
gens are associated with polysaccharides, bearing repetitive
structures (Obukhanych & Nussenzweig, 2006). The repetitive
Fig 3. Shows the hydrolysis of PEGasparaginase and the detection of anti-succinate linker antibodies. (A) Shows the hydrolysis of mPEG5,000 from
PEGasparaginase at pH 9.5 and room temperature. After approximately 12 h, the concentration free mPEG5k stabilizes, showing complete hydrol-
ysis of mPEG5,000. (B) Shows the relative titers to the SS-linker conjugated to BSA. The relative titers were obtained by dividing the titers mea-
sured by the minimal required dilutions (759 for both IgG and IgM). Percentages indicate fraction of patients positive for anti-succinate
antibodies. In (C) patients were screened for the n-ethyl maleimide group conjugated to BSA (random linker) and BSA. This figures shows that
the antibodies were specific for the succinate group. (D) Shows IgG (●) and IgM (□) normalized dose-response curve of BSA-SS coated plates
in presence of different concentrations of hydrolyzed PEGasparaginase.
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ethylene oxide (-CH2-CH2-O-) units of PEG may be recog-
nized by the same mechanism as these T-cell independent type
II antigens.
In line with our observations, Rau et al, 2017 reported
lower anti-PEG IgM titers than IgG in patients with an aller-
gic reaction to PEGcrisantaspase, a PEGylated form of
recombinant Erwinia asparaginase using glutaric acid spacer
as a linker, administered after a hypersensitivity reaction to
PEGasparaginase. Whereas anti-PEG antibodies detected in
animals are predominantly reported as anti-PEG IgM,
human studies primarily show anti-PEG IgG (Verhoef et al,
2014; Yang & Lai, 2015).
In our study, 58% (14/24) of the patients without any
reaction had pre-existing anti-PEG IgG, and 21% anti-PEG
IgM. Although anti-PEG antibodies were already described in
the healthy population (Armstrong et al, 2003), this study
shows that the antibodies can be developed relatively early in
life and may have been formed during previous exposure to
PEG containing food or cosmetic products (Richter & Aker-
blom, 1984; Leger et al, 2001; Armstrong et al, 2003; Liu
et al, 2011). The fact that also patients without neutralization
had anti-PEG antibodies proves that these antibodies do not
necessarily possess neutralizing characteristics. Why these
antibodies result in a neutralizing hypersensitivity reaction in
only part of the patients should be further investigated.
Our study is the first to report that antibodies can be
formed against the succinate succinimidyl linker and pro-
vides clinical evidence that use of a cleavable linker that
remains on the therapeutic protein upon hydrolysis can
induce the formation of anti-drug antibodies. Although
in vivo no such basic conditions are expected, the hydrolysis
results are intended to show that the linker is hydrolysis
prone. As there are several hydrolytic enzymes in the body
present, we raise the hypothesis that these are responsible for
hydrolyzing the PEG from the protein. Anti-SS-linker anti-
bodies were predominantly found during induction. How-
ever, all patients positive for anti-SS-linker antibodies also
had anti-PEG antibodies. We could, therefore, not identify if
these anti-linker antibodies only bind to the linker or also
induce an immunological response. The anti-PEG antibodies
may also be directed towards both the linker and the PEG
chain. Angiolillo et al. studied the presence of antibodies and
occurrence of hypersensitivity reactions in patients treated
with PEGasparaginase or Calaspargase pegol, a PEGylated
E. coli asparaginase with a succinimidyl carbamate linker.
Treatment with this type of asparaginase seems to result in a
less rapid clearance and slightly less hypersensitivity reactions
during induction (3% vs. 7%, although not significant)
(Angiolillo et al, 2014). These findings may imply that
PEGylation with the SS-linker results in a more immuno-
genic therapeutic than by the other linker.
Anti-PEGasparaginase antibodies are frequently measured
by various study groups with ELISA using a standard car-
bonate buffer of pH 90–95. However, PEG hydrolyses from
PEGasparaginase at pH95 (Fig 3A). Thus, by using this buf-
fer only anti-E. coli asparaginase and anti-SS-linker antibod-
ies can be measured. Therefore, we recommend to coat
plates using a buffer of pH74 for PEGasparaginase antibody
detection.
In conclusion, first, we identified that anti-PEG antibodies
play a significant role in the neutralization of PEGasparagi-
nase, mainly during the first doses in induction, since part of
the patients are only positive for this type of antibodies. Sec-
ond, anti-asparaginase antibodies are almost exclusively
developed during hypersensitivity reactions after an asparagi-
nase-free interval in our patient cohort. Thus, patients with a
reaction during the first doses of PEGasparaginase theoreti-
cally could switch to the less expensive native E. coli asparag-
inase for adequate treatment, reserving Erwinia asparaginase
as an extra alternative. Third, pre-existing anti-PEG antibod-
ies are found in part of the patients with no clinical effect.
Therefore, these antibodies not necessarily trigger a hypersen-
sitivity reaction and screening of anti-PEG antibodies is not
a good marker to estimate patient outcome. And fourth, the
discovery of the SS-linker as a neo-antigen shows that
PEGylation through an unstable linker remaining on the
therapeutic protein upon hydrolysis can serve as a hapten.
Future drug development efforts should therefore focus on
stable PEG-linker chemistries.
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